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We read with interest the article by Hézode et al., in which they
describe the week 16 interim results from the CUPIC study, a
large French multicenter prospective cohort study [1]. Given
the strict inclusion criteria of protease inhibitors (PI) phase III tri-
als, the cirrhotic group was underrepresented and composed of
highly selected patients in these studies [2–5]. Therefore, efﬁcacy
and safety concerns about ﬁrst-generation PI-based therapy in
‘‘real-life’’ cirrhotic patients were raised. The CUPIC investigators
found that albumin levels <35 g/L and platelet count 6100,000/
mm3 were independent predictors of death and severe complica-
tions, and the risk of these events in patients with both predictors
was worryingly high (44.1%). The ﬁndings from the CUPIC study,
important as they are, need to be qualiﬁed given two important
caveats that we would like to discuss.
First, as the authors mentioned in the methods section, the
safety interim analysis was not pre-speciﬁed in the original pro-
tocol and the sample size was not estimated for this purpose.
As a result, the study was probably underpowered to investigate
factors associated with such a low incidence event (death or
severe complications). This issue is even more relevant when
we analyze the number of variables included in the multivariate
analysis presented in Table 3. It is generally recommended that
a minimum of 10 events per variable should be used in logistic
regression models, since increasing bias and variability, unreli-
able conﬁdence interval coverage, and problems with model con-
vergence emerge as the events per variable ratio declines below
10 and especially below ﬁve [6,7]. In the article by Hézode and
colleagues, the multivariate analysis included 12 variables found
to be associated with death or severe complications in univariate
analysis, whereas only 32 events occurred (2.7 events per variable
included). The adequate interpretation of the model is further
hampered by the probable signiﬁcant multicollinearity between
several independent variables included, like bilirubin, albumin,
Child-Pugh score and MELD score.
Based on the ﬁgures shown on the article’s Table 4, we have
calculated the accuracy parameters for albumin levels <35 g/L
and platelet count 6100,000/mm3, either alone or in combina-
tion, for the prediction of death or severe complications (Table 1).
Albumin exhibited higher speciﬁcity as compared to platelet
count (89% vs. 79%), with comparable sensitivity (57% vs. 60%).
Moreover, the positive likelihood ratio (LR+) was much higher
for low albumin levels than low platelet count (5.02 vs. 2.82).
When both parameters were used in combination, there was aJournal of Hepatology 20
cess under CC BY-NC-ND license.modest gain in speciﬁcity (95%) and a signiﬁcant increase in
LR+ (10.50). Given that the LR+ tells us how much to increase
the probability of event if the test is positive, these results
indicate that a serum albumin level <35 g/L can indeed be
regarded as a good predictor of death and severe complications
in cirrhotic patients treated with ﬁrst-generation PI-based
regimens, particularly when associated with a platelet count
6100,000/mm3. Interestingly, the negative predictive value was
high (>95%) for all parameters, which can prove to be a reassuring
ﬁnding and a valuable tool if conﬁrmed in other cohorts.
In conclusion, although we acknowledge the unquestionable
importance of the CUPIC study, we believe that its results do
not support the author’s deﬁnitive conclusion that treatment-
experienced cirrhotic patients with platelet count and albumin
levels below the mentioned cutoffs should not be treated with
telaprevir or boceprevir. Conceivably, additional studies will be
able to conﬁrm CUPIC’s ﬁndings, or will even propose alternative
strategies for high risk patients, like antibiotic prophylaxis or low
accelerating dose regimen for interferon. Until then, we believe
that triple therapy should not be denied to patients who do not
meet the proposed albumin/platelet criteria, but rather they
should be treated in specialized centers with liver transplant
programs, by experienced hepatologists. The current approved
PI-based regimen will probably be the standard-of-care for HCV
patients for many years in several countries and, even though
IFN-free regimens are coming, it may be a very distant reality
for many cirrhotic patients at risk for decompensation in the near14 vol. 60 j 229–236
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Table 1. Performance of albumin levels and platelet count alone and in combination as predictors of death or severe complications according to the CUPIC Study
data.
Death or severe 
complications
All patients 
(n = 429) n
No 
(n = 400)
Yes 
(n = 30)
Accuracy 
(%)
Sensitivity Specificity
(%) (%)
PPV 
(%)
NPV 
(%)
LR+ LR-
Albumin (n = 74) ≥35 367 354 13
87 57 89 27 97 5.02 0.49
<35 62 45 17
Platelet count (n = 129) >100,000 326 314 12
77 60 79 19 96 2.82 0.51
≤100,000 103 85 18
Albumin <35 g/L and 
platelet count 
≤100,000/mm3
No 395 380 15
92 50 95 44 96 10.50 0.53Yes 34 19 15
PPV, positive predictive value; NPV, negative predictive value; LR+, positive likelihood ratio; LR, negative likelihood ratio.
Reply to: From the CUPIC study: Great times are not coming (?)
To the Editor:
Carvalho-Filho and colleagues raised two comments regarding
our paper [1].
The ﬁrst comment relates to the fact that the safety interim
analysis may have been underpowered, and that the number of
variables included in the multivariate analysis did not respect
the 10 events per variable ratio (EVR) rule. The second comment
relates to bias induced by potential multicollinearity between
covariates tested in multivariate models. In reply we will address
three points.
(1) Might associations between death or complications with
albumin and platelet count be a ‘false positive result’?
Indeed, the non-respect of the 10 events per variable rule is
mostly known to increase the type I error, i.e., the risk of a
signiﬁcant association when no association truly exists. First,
the relevance of the 10 events per variable rule has been dis-
cussed and further simulation studies showed that, in a logistic
model with two binary predictors such as ours, the inﬂation of
type I error is moderate [2]. Second, and most importantly, the
positive associations with albumin and platelet count were not
exploratory post hoc ﬁndings but were a priori hypothesized asso-
ciations, which limited the risk of false positive results. Third, we
found a clear dose-effect relationship with each of these two
factors when considered as a continuous variable and deaths or
severe complications (Table 1) – this argues for a direct or indi-
rect causality link between albumin or platelet count and severe
outcome.
Therefore, we do believe that independent associations
between albumin and platelet count are real and not the conse-
quence of inﬂated type I error due to low EVR.
(2) Might odds-ratios estimates be biased given the low num-
ber of events and potential multicollinearity?
First, we performed backward logistic models, and thus, the
ﬁnal model (with an event per variable ratio of 15) did not
include any other predictor than albumin and platelet count,
which limited the bias in estimating the strengths of association
and avoided any collinearity problem in ﬁnal model estimates.
Second, we also performed additional analyses using 1000 boot-
strap samples to derive bias-corrected conﬁdence intervals. The
bootstrap estimates of conﬁdence intervals were (3.27–15.6) for
albumin <35 g/L, and (1.43–7.85) for platelet count 6100 
109/L, conﬁrming our ﬁgures.
Therefore we do believe that our estimates are robust and
were not affected by our analytic strategy.
(3) Might there be any other missed predictor of the risk of
death or complications?
Of course, we cannot exclude that our study may have been
underpowered to detect other potential associations. However,
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